Found 115 matching trials
Study of the Inappropriate Secretion of FGF23 in Patients Followed in Hospital in a Context of Hypophosphatemia N/A The discovery of FGF23, the missing link in the long researched and finally...
Show More Location
Chu Clermont Ferrand
Learn More & Join Trial
Catheterization to Locate Mesenchymal Tumors in Patients With Tumor-Induced Osteomalacia or Oncogenic Osteomalacia N/A This study will use a procedure called selective venous catheterization in ...
Show More Location
National Institutes of Health Clinical Center, 9000 Rockville Pike
Learn More & Join Trial
Sevelamer, FGF-23 and Endothelial Dysfunction in Chronic Kidney Disease (CKD) PHASE4 Vascular calcification and endothelial dysfunction (ED) contribute to the d...
Show More Location
Gulhane School of Medicine
Learn More & Join Trial
Effects of a Non-Calcium Based Phosphate Binder on FGF23 Levels in Chronic Kidney Disease EARLY_PHASE1 Fibroblast Growth Factor 23 (FGF23) is a molecule that has been implicated ...
Show More Location
Penn State Milton S. Hershey Medical Center
Learn More & Join Trial
FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease NA FGF-23 is a newly described protein that is an important regulator of phosp...
Show More Learn More & Join Trial
The Impact of Selected Factors on the Cardiovascular System in Chronic Kidney Disease N/A Chronic kidney disease (CKD), is characterized by accelerated development o...
Show More Location
Poznan University of Medical Sciences
Learn More & Join Trial
Time Course of Circulating Myocardial Biomarkers After a TASH Procedure. N/A The study evaluates the released myocardial substances in blood of HOCM pat...
Show More Location
Aachen University Hospital; Medical Clinic I - Cardiology, Pneumology, Angiology and Internal Intensive Medicine
Learn More & Join Trial
Fibroblast Growth Factor-23 (FGF-23) is Independently Associated With Left Ventricular Mass Index (LVMI) and Myocardial Performance Index (MPI) in Haemodialysis Patients N/A Serum FGF-23 levels will be measured in patients with a history of coronary...
Show More Location
Diskapi Training and Research Hospital
Learn More & Join Trial
Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets PHASE3 A 52 week, open label trial to assess the safety and efficacy of KRN23, an ...
Show More Location
The Focus Center, PC
Learn More & Join Trial
Fibroblast Growth Factor 23 in Chronic Respiratory Failure N/A Fibroblast growth factor 23 (FGF23) is a key hormone of the mineral metabol...
Show More Location
Multiple Locations
Learn More & Join Trial